Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

agro-alliance (australia) pty ltd - glyphosate present as the isopropylamine salt - soluble concentrate - glyphosate present as the isopropylamine salt glycine active 450.0 g/l - herbicide - annual grass weed - seed set control | citrus fruit orchard | fallow weed control - prior to sowing | forest | non-agricultural - african boxthorn | amaranth or amaranthus | amsinckia | annual or wimmera ryegrass | annual phalaris | annual ryegrass | barley grass | barnyard grass or water grass | barnyard or water grass | blackberry | bladder ketmia | bracken | brome grass | caltrop or yellow vine | camel or afghan melon | capeweed | carpet grass | cat's ear or flatweed | chickweed | cocksfoot | couch grass | cudweed | dock - seedling | fumitory | ground or annual ground cherry | hedge or wild mustard | johnson grass | kikuyu grass | liverseed or urochloa grass | mexican poppy | mintweed | native bluebell | new zealand spinach | noogoora burr | nutgrass | paspalum | paterson's curse | perennial pigweed | phalaris | pigweed spp. | ryegrass | saffron thistle | scotch thistle | silver grass or rat's-tail fescue | silvergrass - aristida contorta | skeleton weed - fully emerged rosettes | sorrel | soursob or oxalis | sow or milk thistle | spear or black thistle | spiny burrgrass or gentle annie | spiny emex | spurge | stink grass | stinking

Australia - English - Department of Health (Therapeutic Goods Administration)

esl biosciences australia 2012 pty ltd - ct943 - instrument/analyser ivds - vision hema is a microscope system for blood cell identification and pre classification. it's aim is to automate and simplify the procedure of blood smear analysis

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

yandilla mustard oil enterprise pty. limited - mustard powder - unknown - mustard powder food-plant active 0.0 - active constituent

United States - English - NLM (National Library of Medicine)

b. braun medical inc. - hydroxyethyl starch 130/0.4 (unii: 1gvo236s58) (hydroxyethyl starch 130/0.4 - unii:1gvo236s58), sodium chloride (unii: 451w47iq8x) (sodium cation - unii:lyr4m0nh37, chloride ion - unii:q32zn48698) - hydroxyethyl starch 130/0.4 6 g in 100 ml - 6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride injection is indicated for the treatment and prophylaxis of hypovolemia in adults and children. it is not a substitute for red blood cells or coagulation factors in plasma. - do not use hydroxyethyl starch (hes) products, including 6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride injection, in critically ill adult patients, including patients with sepsis, due to increased risk of mortality and renal replacement therapy (rrt).  - do not use hes products, including 6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride injection, in patients with severe liver disease. - do not use hes products, including 6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride injection, in patients with known hypersensitivity to hydroxyethyl starch [see general warnings and precautions (5.1) ] - do not use hes products in clinical conditions with volume overload.  - do not use hes products in patients with pre-existing coagulation or bleeding disorders.  - do not use h

United States - English - NLM (National Library of Medicine)

hospira, inc. - hydroxyethyl starch 130/0.4 (unii: 1gvo236s58) (hydroxyethyl starch 130/0.4 - unii:1gvo236s58) - hydroxyethyl starch 130/0.4 6 g in 100 ml - voluven ® (6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride injection) is indicated for the treatment and prophylaxis of hypovolemia in adults and children. it is not a substitute for red blood cells or coagulation factors in plasma. - do not use hydroxyethyl starch (hes) products, including voluven ® , in critically ill adult patients, including patients with sepsis, due to increased risk of mortality and renal replacement therapy (rrt). - do not use hes products, including voluven ® , in patients with severe liver disease. - do not use hes products, including voluven ® , in patients with known hypersensitivity to hydroxyethyl starch [see general warnings and precautions (5.1) ] - do not use hes products in clinical conditions with volume overload. - do not use hes products in patients with pre-existing coagulation or bleeding disorders. - do not use hes products in patients with renal failure with oliguria or anuria not related

United States - English - NLM (National Library of Medicine)

h and p industries, inc. dba triad group - starch, corn (unii: o8232ny3sj) (starch, corn - unii:o8232ny3sj) - starch, corn 0.51 g - protectant - provides temporary relief of the itching, burning and discomfort associated with hemorrhoids and other anorectal disorders - provides a coating to protect irritated tissue

United States - English - NLM (National Library of Medicine)

allergan, inc. - triptorelin pamoate (unii: 08an7wa2g0) (triptorelin - unii:9081y98w2v) - triptorelin 3.75 mg in 2 ml - trelstar is indicated for the palliative treatment of advanced prostate cancer [see  clinical studies (14) ]. trelstar is contraindicated in individuals with a known hypersensitivity to triptorelin or any other component of the product, or other gnrh agonists or gnrh [see warnings and precautions (5.1) ]. risk summary based on findings in animal studies and mechanism of action, trelstar can cause fetal harm when administered to a pregnant woman [see clinical pharmacology (12.1) ] . expected hormonal changes that occur with trelstar treatment increase the risk for pregnancy loss. in animal developmental and reproductive toxicology studies, daily administration of triptorelin to pregnant rats during the period of organogenesis caused maternal toxicity and embryo-fetal toxicities, including loss of pregnancy, at doses as low as 0.2, 0.8, and 8 times the estimated human daily dose based on body surface area. advise pregnant patients and females of reproductive potential of the potential risk to the fetus. dat

United States - English - NLM (National Library of Medicine)

sandoz inc - norgestimate (unii: c291hfx4dy) (norgestimate - unii:c291hfx4dy), ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u) - norgestimate 0.25 mg - estarylla™ (norgestimate and ethinyl estradiol tablets) are indicated for use by females of reproductive potential to prevent pregnancy [see clinical studies (14)] . do not prescribe norgestimate and ethinyl estradiol to women who are known to have the following conditions: - use of hepatitis c drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, due to the potential for alt elevations [seewarnings and precautions (5.3) ] there is little or no increased risk of birth defects in women who inadvertently use cocs during early pregnancy. epidemiologic studies and meta-analyses have not found an increased risk of genital or non-genital birth defects (including cardiac anomalies and limb reduction defects) following exposure to low dose cocs prior to conception or during early pregnancy. do not administer cocs to induce withdrawal bleeding as a test for pregnancy. do not use cocs during pregnancy to treat threatened or habitual abortion. advise the nursing mother to use other f

United States - English - NLM (National Library of Medicine)

xiromed, llc. - norgestimate (unii: c291hfx4dy) (norgestimate - unii:c291hfx4dy), ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u) - norgestimate 0.25 mg - estarylla (norgestimate and ethinyl estradiol tablets) are indicated for use by females of reproductive potential to prevent pregnancy [see clinical studies (14)] . estarylla is contraindicated in females who are known to have or develop the following conditions: - use of hepatitis c drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, due to the potential for alt elevations [seewarnings and precautions (5.3)] there is little or no increased risk of birth defects in women who inadvertently use cocs during early pregnancy. epidemiologic studies and meta-analyses have not found an increased risk of genital or non-genital birth defects (including cardiac anomalies and limb reduction defects) following exposure to low dose cocs prior to conception or during early pregnancy. do not administer cocs to induce withdrawal bleeding as a test for pregnancy. do not use cocs during pregnancy to treat threatened or habitual abortion. advise the nursing mother to use other forms of cont

United States - English - NLM (National Library of Medicine)

verity pharmaceuticals inc. - triptorelin pamoate (unii: 08an7wa2g0) (triptorelin - unii:9081y98w2v) - trelstar is indicated for the treatment of advanced prostate cancer [see  clinical studies (14) ]. trelstar is contraindicated in individuals with a known hypersensitivity to triptorelin or any other component of the product, or other gnrh agonists or gnrh [see warnings and precautions (5.1) ]. risk summary based on findings in animal studies and mechanism of action, trelstar can cause fetal harm when administered to a pregnant woman [see clinical pharmacology (12.1) ] . expected hormonal changes that occur with trelstar treatment increase the risk for pregnancy loss. in animal developmental and reproductive toxicology studies, daily administration of triptorelin to pregnant rats during the period of organogenesis caused maternal toxicity and embryo-fetal toxicities, including loss of pregnancy, at doses as low as 0.2, 0.8, and 8 times the estimated human daily dose based on body surface area. advise pregnant patients and females of reproductive potential of the potential risk to the fetus. data animal data studies in pregnant rats administered triptorelin at doses of 2, 10, and 100 mcg/kg/day (approximately equivalent to 0.2, 0.8, and 8 times the estimated human daily dose based on body surface area) during the period of organogenesis demonstrated maternal toxicity and embryo-fetal toxicities.  embryo-fetal toxicities consisted of pre-implantation loss, increased resorption, and reduced mean number of viable fetuses at the high dose.  teratogenic effects were not observed in viable fetuses in rats or mice.  doses administered to mice were 2, 20, and 200 mcg/kg/day (approximately equivalent to 0.1, 0.7, and 7 times the estimated human daily dose based on body surface area).     the safety and efficacy of trelstar have not been established in females.  there are no data on the presence of triptorelin in human milk, the effects of the drug on milk production, or the effects of the drug on the breastfed child.  because of the potential for serious adverse reactions in a breastfed child from trelstar, a decision should be made to either discontinue breastfeeding, or discontinue the drug taking into account the importance of the drug to the mother. infertility males based on mechanism of action, trelstar may impair fertility in males of reproductive potential [see clinical pharmacology (12.1)] . safety and effectiveness in pediatric patients have not been established. prostate cancer occurs primarily in an older population.  clinical studies with trelstar have been conducted primarily in patients ≥ 65 years [see  clinical pharmacology (12.3) and clinical studies (14) ]. subjects with renal impairment had higher exposure than young healthy males [see  clinical pharmacology (12.3) ]. subjects with hepatic impairment had higher exposure than young healthy males [see  clinical pharmacology (12.3) ].